The power and potential of doxorubicin-DNA adducts
- PMID: 16036566
- DOI: 10.1080/15216540500079093
The power and potential of doxorubicin-DNA adducts
Abstract
Doxorubicin (trade name Adriamycin) is a widely used anticancer agent which exhibits good activity against a wide range of tumors. Although the major mode of action appears to be normally as a topoisomerase II poison, it also exhibits a number of other cellular responses, one of which is the ability to form adducts with DNA. For adduct formation doxorubicin must react with cellular formaldehyde to form an activated Schiff base which is then able to form an aminal (N-C-N) linkage to the exocyclic amino group of guanine residues. The mono-adducts form primarily at G of 5'-GCN-3' sequences where the chromophore of the drug is intercalated between the C and N base pair. The structure of the adducts has have been well defined by 2D NMR, mass spectrometry and X-ray crystallography. The formation of these anthracycline adducts in cells grown in culture has been unequivocally demonstrated. The source of formaldehyde in cells can be endogenous, provided by coadministration of prodrugs that release formaldehyde or by prior complexation of anthracyclines with formaldehyde. Since the adducts appear to be more cytotoxic than doxorubicin alone, and also less susceptible to drug-efflux forms of resistance, they offer new approaches to improving the anticancer activity of the anthracyclines.
Similar articles
-
Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death.Cancer Res. 2006 May 1;66(9):4863-71. doi: 10.1158/0008-5472.CAN-05-3410. Cancer Res. 2006. PMID: 16651442
-
DNA repair in response to anthracycline-DNA adducts: a role for both homologous recombination and nucleotide excision repair.Mutat Res. 2008 Feb 1;638(1-2):110-21. doi: 10.1016/j.mrfmmm.2007.09.005. Epub 2007 Sep 16. Mutat Res. 2008. PMID: 17961607
-
Redox pathway leading to the alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin.J Med Chem. 1997 Apr 11;40(8):1276-86. doi: 10.1021/jm960835d. J Med Chem. 1997. PMID: 9111302
-
Potential Therapeutic Advantages of Doxorubicin when Activated by Formaldehyde to Function as a DNA Adduct-Forming Agent.Curr Top Med Chem. 2015;15(14):1409-22. doi: 10.2174/1568026615666150413154512. Curr Top Med Chem. 2015. PMID: 25866273 Review.
-
Barminomycin, a model for the development of new anthracyclines.Anticancer Agents Med Chem. 2010 Jan;10(1):70-7. doi: 10.2174/1871520611009010070. Anticancer Agents Med Chem. 2010. PMID: 19807684 Review.
Cited by
-
DNA damage and repair in human cancer: molecular mechanisms and contribution to therapy-related leukemias.Int J Environ Res Public Health. 2012 Aug;9(8):2636-57. doi: 10.3390/ijerph9082636. Epub 2012 Jul 27. Int J Environ Res Public Health. 2012. PMID: 23066388 Free PMC article. Review.
-
Novel Anthracycline Utorubicin for Cancer Therapy.Angew Chem Int Ed Engl. 2021 Jul 26;60(31):17018-17027. doi: 10.1002/anie.202016421. Epub 2021 Jun 1. Angew Chem Int Ed Engl. 2021. PMID: 33908690 Free PMC article.
-
Disparate impact of butyroyloxymethyl diethylphosphate (AN-7), a histone deacetylase inhibitor, and doxorubicin in mice bearing a mammary tumor.PLoS One. 2012;7(2):e31393. doi: 10.1371/journal.pone.0031393. Epub 2012 Feb 23. PLoS One. 2012. PMID: 22384017 Free PMC article.
-
Importance of intracellular pH in determining the uptake and efficacy of the weakly basic chemotherapeutic drug, doxorubicin.PLoS One. 2012;7(4):e35949. doi: 10.1371/journal.pone.0035949. Epub 2012 Apr 26. PLoS One. 2012. PMID: 22563426 Free PMC article.
-
Poly (ADP-ribose) polymerase as a novel therapeutic _target in cancer.Clin Cancer Res. 2010 Sep 15;16(18):4517-26. doi: 10.1158/1078-0432.CCR-10-0526. Epub 2010 Sep 7. Clin Cancer Res. 2010. PMID: 20823142 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
